Condition: Urothelial Cancer · Sponsor: Bristol-Myers Squibb
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0167 | Gilbert, Arizona, United States | Not Yet Recruiting |
| Local Institution - 0162 | Fullerton, California, United States | Not Yet Recruiting |
| Palo Alto Center-Palo Alto Medical Foundation Research Institute | Palo Alto, California, United States | Recruiting |
| Sutter Health - Sutter Institute for Medical Research | Sacramento, California, United States | Recruiting |
| University of California Davis (UC Davis) Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Pacific Hematology Oncology Associates | San Francisco, California, United States | Recruiting |
| Sutter Santa Rosa | Santa Rosa, California, United States | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Denver, Colorado, United States | Recruiting |
| Local Institution - 0245 | Dillon, Colorado, United States | Withdrawn |
| Shaw Cancer Center | Edwards, Colorado, United States | Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Local Institution - 0247 | Miami, Florida, United States | Not Yet Recruiting |
+ 151 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07106762